University of Oxford scientists performed a meta-analysis of the GLP-1 agonists Lyxumia (lixisenatide), Victoza (liraglutide), Ozempic (semaglutide), and Bydureon (extended-release exenatide), to evaluate their affect on heart health.
The type 2 diabetes medicine are all designed to assist decrease blood sugar ranges by stimulating insulin and suppressing glucagon after meals.
In individuals with type 2 diabetes, GLP-1 therapy led to a 10% decreased threat for mixture of heart assault, stroke or loss of life from heart illness; a 13% per cent decreased threat of loss of life from heart illness particularly; and a 12% decreased threat of loss of life from any trigger.
“Our findings show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns,” stated the researchers.
The meta-analysis used information from trials the place GLP-1 medicine have been in contrast with placebo in adults with type 2 diabetes. The main outcomes of the analysis included results of cardiovascular mortality, heart assault and non-fatal stroke.
Four trials have been recognized, and alongside improved heart health advantages, no vital results have been noticed on hospital admission for unstable angina or heart failure. Moreover, no vital variations have been noticed relating to extreme hypoglycemia, pancreatitis or pancreatic most cancers.
“GLP-1 receptor agonists have a favourable risk-benefit balance overall, which should allow the choice of drug to be individualised to each patient’s needs,” added the researchers.
The outcomes have been printed in The Lancet journal.
